Emerging therapies for osteoporosis.
This article reviews the conceptual framework for agents that are antiresorptive or anabolic, including pathways that affect bone formation and resorption, and the steps in those pathways that are targets for new therapeutic agents. This article discusses novel antiresorptive and anabolic agents in development. Recent developments that link bone remodeling with serotonin in the gastrointestinal system and the central nervous system via the sympathetic nervous system may change the paradigm for skeletal remodeling. Novel anabolic agents in development include antibodies that target molecules involved in Wnt signaling.
Orthopedic and Rheumatology Institute, Department of Rheumatology, Center for Osteoporosis and Metabolic Bone Disease, Cleveland, OH, USA. dealc@ccf.org
Chad
C
Deal
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002113:Calcification, Physiologic / Q000187:drug effects* / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D009566:Nitrates / Q000494:pharmacology; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism; D012701:Serotonin / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology
D050071:Bone Density Conservation Agents; D004791:Enzyme Inhibitors; D009566:Nitrates; D012701:Serotonin